Market Newsdesk

VANCOUVER, British Columbia, May 18, 2021 (GLOBE NEWSWIRE) — Eden Empire Inc. (CSE: EDEN) (the “Company” or “EDEN™“) is thrilled to announce that it has received its Approval in Principle (“AIP”) from the Liquor & Cannabis Regulation Branch of the Province of British Columbia (the “LRCB”) for a cannabis retail store in Vancouver’s West End. The location will serve as EDEN’s flagship store located at 1674 Davie Street in Vancouver, British Columbia. Receiving AIP from the LRCB is one of the final steps required in licensing a cannabis retail store in the Province of British Columbia.

Key Takeaways

• Located in the Lower Davie Village area, this location is considered one of the most densely populated and expanding neighborhoods in Vancouver.
• Sits just steps away from the bustling Sunset Beach area, a BC Liquor store, and numerous adult-focused establishments.

Gerry Trapasso, Director & CEO, commented, “We are excited to add this flagship location to the numerous cannabis retail stores anticipated to operate under the EDEN brand in Vancouver. This specific location was previously a popular cannabis store and we look forward to welcoming back those local customers. Receiving AIP from the LCRB marks a significant milestone for the Company. We are ready for further expansion in the Province of British Columbia to showcase what truly sets EDEN’s brand and customer experience apart.”

For further information or should you have any questions, please feel free to email us at [email protected].

Gerry Trapasso, CEO

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

About Eden Empire

Eden Empire is in the business of investments and operations in the cannabis sector and engaging in retail cannabis sales. Eden Empire intends to expand its retail operations in Canada and to expand its business to cannabis cultivation, extraction and processing‎ and become a fully integrated cannabis product company in the United States.

Eden Empire has an award winning and established nationwide brand, including a substantial intellectual property portfolio, and a dedicated management team with extensive cannabis industry experience. Upon completion of Eden Empire’s currently intended acquisitions, and approval to operate its retail locations, the Company is expected to have a significant retail cannabis footprint in Canada and Michigan. Retail cannabis operations are an emerging sector with significant cash flow potential.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “upon” “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information include, but are not limited to, statements with respect to the completion by the Company of the final steps required to license its flagship cannabis retail store in the Province of British Columbia; the future customer base of the Company’s flagship cannabis retail store;; the future operation of numerous cannabis stores in Vancouver; the Company’s future expansion and operations of retail cannabis stores in the United States and Canada; the Company expanding its business to cannabis cultivation, extraction and processing and becoming a fully integrated cannabis company in the United States; the completion of the Company’s currently intended acquisitions; the receipt of all necessary licenses and approvals to operate the Company’s retail locations; and the proposed future transactions Eden may undertake and their expected timing.

Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Eden Empire to control or predict, that may cause Eden Empire’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: Eden Empire may not obtain the requisite regulatory approvals and may not begin operating cannabis retail or cultivation and processing operations; that the actual use of proceeds may differ from those currently stated; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; currency fluctuations; regulatory restrictions and the possibility for changes in laws, rules, and regulations in the industry; liability, competition, loss of key employees and other related risks and uncertainties. Eden Empire does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.

OTTAWA, May 18, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced that management will participate in BMO Capital Markets 16^th Annual Farm to Market Conference. Sebastien St-Louis, Chief Executive Officer, and Trent MacDonald, Chief Financial Officer, will participate in a fireside chat hosted by Tamy Chen, Equity Research Analyst covering cannabis at BMO, on Thursday, May 20, 2021 at 9:20 a.m. ET.

Participants may access a live webcast of the fireside chat by going to the “Events” page on hexocorp.com. For more information, please contact your BMO Capital Markets representative.

About HEXO Corp (TSX: HEXO; NYSE: HEXO)

HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. The Company serves the Canadian adult-use markets under its HEXO, HEXO Plus, Up, Original Stash and Bake Sale brands and the medical market under HEXO medical cannabis. For more information, please visit hexocorp.com.

Investor Relations:


[email protected]





www.hexocorp.com

 

Media Relations:
(819) 317-0526
[email protected]

UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present at the 2021 UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 1:00 p.m. ET.

The presentation will be webcast and can be accessed from the investor relations section of the company’s website at www.lavatherapeutics.com.

About LAVA

LAVA Therapeutics N.V. is a clinical stage biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematological malignancies based on its proprietary platform. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells and induce gamma-delta T cell-mediated immunity through activation of Vγ9Vδ2 T cells upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematologic malignancies is anticipated to generate top line clinical data in the first half of 2022. The Company expects to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the second half of 2021. For more information, please visit www.lavatherapeutics.com.

Contact

Chelcie Lister
THRUST Strategic Communications
[email protected]

Total consideration is $286 million, reduced by $12 million of working capital to be retained by Teleflex

Assets to be divested generated $139M in 2020 revenue, with 2021 growth expected to be approximately flat

2021 headwinds are estimated at $28-32 million in revenue and $0.10-$0.15 in adjusted diluted earnings per share

Teleflex is maintaining its current 2021 adjusted diluted earnings per share guidance range

WAYNE, Pa., May 18, 2021 (GLOBE NEWSWIRE) — Today, Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, announced that it has entered into a definitive agreement to sell a significant portion of its Respiratory business to Medline Industries, Inc. (“Medline”) for $286 million in cash, reduced by $12 million in working capital not transferring to Medline. The Teleflex respiratory product lines that will be divested include oxygen and aerosol therapy, active humidification, non-invasive ventilation, and incentive spirometers, which generated $139 million in revenue in 2020. The transaction is expected to close early in the third quarter of 2021, subject to customary regulatory approvals and other closing conditions.

“Following a comprehensive review of our strategy and core capabilities, our Board of Directors and management team decided that divesting a significant portion of our Respiratory business will enable Teleflex to focus further on executing in our core market segments to drive long-term sustainable growth and increase shareholder value,” said Liam Kelly, Chairman, President and Chief Executive Officer of Teleflex. “We expect the proceeds from the divestiture of this business, along with our ability to continue to generate cash from operations, to help us on our journey to execute our strategic plan.” In addition, Mr. Kelly noted, “Following a strong first quarter 2021 performance and the continued recovery in April as outlined on our first quarter 2021 earnings call, we feel confident in maintaining our 2021 full year adjusted earnings per share guidance range, even in light of the dilution from the sale of the respiratory assets. We look forward to providing a full financial update to investors on our second quarter 2021 earnings call. Importantly, this transaction is accretive to our pro-forma revenue growth profile, as well as adjusted gross and operating margins longer term.”

Financial Implications
In 2021, the respiratory product lines that will be divested were expected to generate net revenue approximately flat with the $139 million generated in 2020. Assuming a close to the transaction early in the third quarter of 2021, the company estimates a revenue headwind of $28-32 million and adjusted earnings per share dilution of $0.10-$0.15 in 2021 or approximately 1% of 2021 adjusted earnings per share, net of a manufacturing services agreement that we plan to enter into with Medline upon the initial closing of the sale transaction.

The Company intends to use the divestiture proceeds to pay down debt, augmenting its financial flexibility to support its growth strategy.

Advisors

Guggenheim Securities is acting as financial advisor to Teleflex and Holland & Knight LLP is serving as legal counsel.

Sidley Austin is serving as legal counsel for Medline.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, Hudson RCI^®, LMA^®, Pilling^®, Rüsch^®, UroLift^®, and Weck^® – trusted brands united by a common sense of purpose.

Contacts:
Teleflex Incorporated	Medline
John Hsu	Blair Klein
Vice President, Investor Relations	Vice President, Corporate Communications
610-225-6961	847-643-3308

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. 

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the appointment of Dr. Michael Motz as Chief Commercial Officer, Pharmaceuticals, who will join the company on June 1, 2021.

Dr. Michael Motz is an entrepreneur and executive with over 25 years of industry experience and has held positions of increasing responsibility in both biotech and pharmaceutical companies during his career. He concluded several large transactions, licensing (in- and out-), and acquisitions with EU and U.S. based life science companies, on both the buy side and the sell side. His experiences have also allowed him to gain expert knowledge in drug discovery and development for rare diseases, such as lysosomal storage diseases (LSDs) and certain rare bone disorders.

“Michael brings a rare blend of deal-making experience and scientific know-how to CENTOGENE´s executive leadership team. His proven track record of developing business strategies and forming successful partnerships to advance innovation in various disease areas is an ideal fit with CENTOGENE. Michael will be instrumental in harnessing CENTOGENE’s unique Bio/Databank to transform drug discovery and development for genetic hereditary diseases,” said Andrin Oswald, M.D., Chief Executive Officer of CENTOGENE.

Dr. Michael Motz holds a Ph.D. in Biochemistry from the Max Planck Institute for Evolutionary Anthropology, obtained under the supervision of renowned human geneticist Prof. Dr. h.c. Svante Pääbo. Before joining CENTOGENE, Michael was in leadership positions at several pharma and biotech companies, such as LION Bioscience AG, ALTANA Pharma, Sandoz, F. Hoffmann-La Roche AG, and Zealand Pharma. Most recently, he was Entrepreneur in Residence at BB Pureos Bioventures in Zurich, Switzerland.

“I am thrilled to be joining CENTOGENE and to be able to leverage the full capabilities of the Company’s powerful multiomics platform, with its unprecedented amount of data on rare diseases from patients. In addition to diagnostics, there is tremendous potential to support not only clinical trials in the field with its growing number of pharma partners, but also to apply forward integration of CENTOGENE´s own efforts towards drug discovery and development, based on the Company’s world-leading understanding of rare diseases,” stated Dr. Michael Motz.

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries as of December 31, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners.

Important Notice and Disclaimer

This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities, and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward- looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties, and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on April 15, 2021, and other reports and documents furnished to or filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Media Contact:

CENTOGENE 
Ben Legg 
Corporate Communications
[email protected] 

FTI Consulting 
Bridie Lawlor O’Boyle
+1.917.929.5684 
[email protected]

Los Angeles, CA, May 18, 2021 (GLOBE NEWSWIRE) — (GLOBE NEWSWIRE) — KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) (“KNOS” or the “Company”), an innovation-driven product development and production company that has significantly changed the way air is moved, filtered, and sterilized announced today that the company has opened and will staff an office in Odisha, India. The India office will be a strategic addition to our current offices in the USA and Israel.

When the first wave of the corona virus hit India in March 2020, the Indian Government announced a sweeping national lockdown hours before it went into effect, shutting state borders, suspending inter-state travel, halting businesses and requiring people to stay at home.

CNN reported today that “calls are growing for another nationwide India lockdown. Millions of Indians are living under a mix of locally imposed coronavirus restrictions as the central government resists calls from leading medical experts for a nationwide lockdown.

The Indian Medical Association earlier this month said a “complete, well-planned, pre-announced national lockdown” for 10 to 15 days would give the country’s overstretched health system time to “recoup and replenish both the material and manpower” it needs.

Top US coronavirus advisor, Dr. Anthony Fauci on May 9 said of India: “You’ve got to shut down … you need to break the chain of transmission.”

The Company now markets Kronos patented air purifiers and other Covid related products in India. Also, Kronos will donate PPE and air purification devices to local hospitals though the Kronos Foundation- non-profit organization. Back in beginning on the Pandemic in 2020, Kronos donated its flagship air purifiers to a hospital in Wuhan, China and subsequently to public schools in the U.S.A.

The company is currently hiring India based employees, establishing the company’s first presence in Asia.

CNBC reported recently that the U.S. is giving India raw materials for vaccines, medical supplies to help fight the Covid-19 surge. The Biden administration said that it will immediately make raw materials needed for India’s coronavirus vaccine production available as the country works to counter the surge of Corona infections.

In recent weeks, India has grappled with a staggering rise in new coronavirus infections. Over the weekend, India set another global record for daily cases, bringing the nation’s cumulative total to 16,960,172 cases, according to figures compiled by Johns Hopkins.

“Just as India sent assistance to the United States as our hospitals were strained early in the pandemic, the United States is determined to help India in its time of need,” National Security Council spokeswoman Emily Horne said in a statement on Sunday.

Horne added that the United States would send raw materials required for India to manufacture the Covishield vaccine, as well as therapeutics, rapid diagnostic test kits, ventilators and protective equipment. “The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India, enabling BioE to ramp up to produce at least 1 billion doses of Covid-19 vaccines by the end of 2022,” Horne wrote, adding that the U.S. would also send a team of public health advisors from the Center for Disease Control and USAID to India.

“We are small company but we want to help India in their time of great need,” said Michael Rubinov, Kronos President. “Our wide variety of products are ideal to dramatically reduce airborne transmission as well as monitor interactions and track exposure using our wearable Canario ™ bio-aerosol sensors.”

Kronos Advanced Technologies is offering a wide variety of uniquely patented lines of smart air purifiers for indoor use that removes 99.98% of all pollutants, including smoke, bacteria and viruses, but also does not require any filter replacements, making our air purifiers the lowest cost of ownership in the industry for comparable products. We also offer a personal air purifier for outdoor activity -FIT AIR and recently introduced Invisible e-Mask product (KRONOS – X3000)

Kronos products for safer indoor air quality include Model 3, Model 5 and Model 8 (also marketed as Airdog® products). Also, the Company offers a unique air purifier, Tesla Air, for car use.

 MODEL 5 (MSRP $649.00-on sale for $549.00): Ideal for rooms of up to 1400sq. ft. can disinfect and purify air space every hour (bedrooms, living rooms, etc.) This Model 5  is 26 (H) x 12 (L) x 12 (W) inches, weighs 28.9  pounds, and its power consumption is only 20-60 W (110/240v).

MODEL 8 (MSRP $1,199) ON SALE price $999.00: Ideal for large spaces up to 3000 sq. ft., (businesses, hospitals, schools, universities, hotels, restaurants, including residential spaces such as studio apartments, large living rooms, and home offices.) The MODEL 8 is 30″ (H) x 15″ (W) x 15″, weighs 43 pounds, and its power consumption is 110 W (110/240v). The Model 8 may well be the highest CADR among all air purifiers, including HEPA, and the lowest cost of ownership.

Please visit www.KronosATI.co or www.1800SafeAir.com

About Kronos Advanced Technologies, Inc.

The Company was initially founded in 2002 and funded by the U.S. military to develop electrostatic air movers. Eventually, the Company moved into the consumer air purification business. It began operations as a product development company that invented and significantly changed the way air is moved, filtered, and sterilized. Historically, Kronos has focused on developing, marketing, and selling the Company’s proprietary air movement and purification technology. Serving the Indoor Air Quality (IAQ) market, Kronos technology uses state-of-the-art high voltage patented processes without the use of traditional porous HEPA filters. Kronos-based products move air silently, filter, sterilize, and purify the air while dramatically reducing energy consumption to half of a 60-watt light bulb. Kronos devices can be variable in shape or size and, therefore, have the potential to be scaled-down for air purification in cars or scaled-up in size for industrial and hazardous gas destruction. The technology is currently being implemented in multiple standalone products for businesses, homes, and vehicles of all types -to move, sterilize and filter air, including removing allergens down to 14.6 nanometers, passing through our patented technology -replacing expensive outdated passive HEPA and other filtration type systems. There are broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices. Examples of immediately addressable markets include schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and the cabins of automobiles and commercial aircraft.

Kronos is the first publicly traded Company that accepts DOGE coin as a form of payment for its products, as well as other cryptocurrencies.

Recently, the Company filed for a provisional patent involving an innovative protective face mask with antimicrobial and anti-cellphone radiation protection features. The Company is planning to file additional patents to improve its existing technology as well as enter into new market segments but will continue to market air purifiers and other consumer products. The Company is an exclusive distributor and licensee of the latest generation of air purifiers based on the Company’s CORE technologies. The Company markets its products as Airdog® and KRONOS® brands. All Kronos products come with Kronos Promise ™ -Your Satisfaction is Guaranteed!

Company offices are located in Los Angeles, California.

Shopping portal: https://www.1800safeair.com

Follow KNOS on Twitter: https://twitter.com/kronosati

Follow KNOS on Facebook: https://www.facebook.com/kronosati

Follow KNOS on Instagram: https://www.instagram.com/kronos_ati/

Follow KNOS on Youtube: https://www.youtube.com/channel/UCdtrQDt1R26Ulh8v-S-EpJg

Follow KNOS on Reddit: https://www.reddit.com/user/Kronos_ATI

Follow   KNOS on LinkedIn: https://www.linkedin.com/company/kronos-advanced-techngologies-inc

Contact us via [email protected] or visit https://www.kronosati.co or https://www.1800SafeAIR.com

Disclaimer

This news release does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Kronos Advanced Technologies Inc or any other third party regardless of whether such security, product, or service is referenced in this press release. Furthermore, nothing in this press release is intended to provide tax, legal, or investment advice, and nothing in it should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction. Kronos Advanced Technologies does not represent that the securities, products, or services discussed in this press release are suitable for any particular investor. You are solely responsible for determining whether any investment, investment strategy, security, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You should consult your business advisor, attorney, and/or tax and accounting advisor regarding your specific business, legal, or tax situation.

Social Media Disclaimer and Forward-Looking Statements.

Kronos Advanced Technologies investors and others should note that we announce material information to the public about the Company through various means, including our website (https://www.kronosati.co/investors), through press releases, OTCmarkets filings, public conference calls, via our corporate Social Media accounts, listed above.  We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the OTC Markets at OTCMarkets.com. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.

The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

SOURCE: KRONOS ADVANCED TECHNOLOGIES, Inc

Phone inquiries: 1-800-SAFE-AIR (option #4)

DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin’s president and chief executive officer, and Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe and future president and chief executive officer, are scheduled to present at the following investor conferences scheduled in June:

• Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 9:30 a.m. Eastern Time
• Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 10:30 a.m. Eastern Time

Live audio webcasts of the presentations will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days.

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor Inquiries:

Investor Relations
Amarin Corporation plc
[email protected] (investor inquiries)

Solebury Trout
[email protected]

Media Inquiries:

Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
[email protected] (media inquiries)